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Abstract
To examine whether there are any characteristics of women or their initial tumors that might be useful
for tailoring surveillance recommendations to optimize outcomes. We followed 17,286 women for
up to 5 years after an initial diagnosis of ductal carcinoma in situ (DCIS) or early stage (I/II) invasive
breast cancer diagnosed between 1996 and 2006. We calculated rates per 1,000 women years of
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recurrences and second breast primaries relative to demographics, risk factors, and characteristics of
initial diagnosis: stage, treatment, mode of initial diagnosis. Nearly 4% had a second breast cancer
event (314 recurrences and 344 second breast primaries). Women who used adjuvant hormonal
therapy or were ≥80 years had the lowest rates of second events. Factors associated with higher
recurrence and second primary rates included: initial DCIS or stage IIB, estrogen/progesterone
receptor-negative, younger women (<50 years). Women with a family history or greater breast
density had higher second primary rates, and women who received breast conserving surgery without
radiation had higher recurrence rates. Roughly one-third of recurrences (37.6%) and second primaries
(36.3%) were not screen-detected. Initial mode of diagnosis was a predictor of second events after
adjusting for age, stage, primary treatment, and breast density. A recent negative mammogram should
not falsely reassure physicians or women with new breast symptoms or changes because one-third
of second cancers were interval cancers. This study does not provide any evidence in support of
changing surveillance intervals for different subgroups.
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Background
Breast cancer survivors remain at high risk of a second breast cancer for many years after initial
diagnosis [1,2]. Surveillance mammography aims to detect second breast cancers at earlier
stages to decrease morbidity and ultimately improve survival [3]. Annual surveillance
mammograms and clinical breast examination are recommended for women starting 1 year
after initial diagnosis and no earlier than 6-months after radiation therapy is completed [4].
There are demonstrated benefits of surveillance mammography on reducing breast cancer
mortality [5–7]. In a recent study, surveillance mammography reduced breast cancer mortality
only for women with local recurrences and did not affect regional or distant recurrences; this
provides compelling evidence that early detection of local recurrences drives mortality benefits
[6].
We examined factors associated with surveillance mammography among survivors of early
stage breast cancer in the Breast Cancer Surveillance Consortium (BCSC). We describe time
to recurrence and second primary breast cancers by initial tumor characteristics, risk factors
(including breast density), and mode of initial and subsequent detection.
Methods
This cohort study used pooled BCSC data from four registries: Group Health, Vermont Breast
Cancer Surveillance System, New Hampshire Mammography Network, and New Mexico
Mammography Project [8,9]. Participating registries collect information on mammograms in
their defined catchment areas and link women to pathology and state tumor registries or
regional SEER programs to obtain population-based cancer data. These registries collect
demographic and breast cancer risk factor data from a self-reported questionnaire completed
at each mammogram.
The central statistical coordinating center (SCC) analyzed the data. Each registry and the SCC
have received Institutional Review Board approval for either active or passive consenting
processes or a waiver of consent to enroll participants, link data, and perform analytic studies.
All procedures are Health Insurance Portability and Accountability Act compliant and all
registries and the SCC have received a Federal Certificate of Confidentiality and other
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protection for the identities of women, physicians, and facilities that are subjects of this research
[10].
We included women who had a mammogram and were diagnosed with in situ or early stage
(I/II) [11] breast cancer between 1996 and 2006 (N = 25,640). Starting from the initial breast
cancer diagnosis, we determined whether any further breast cancer diagnoses occurred within
the next 6-months. If so, we used the most invasive diagnosis in that period. We collected stage
(0/I/IIA/IIB) [11], nodal status, estrogen (ER) and progesterone receptor (PR) status, and
primary treatment from tumor registries.
We excluded women with evidence of prior breast cancer (n = 2108), unknown laterality or
bilateral first cancer (n = 769), second breast cancer diagnoses ≤6 months (n = 55), missing
stage or stage ≥III (n = 3436) or no definitive surgery (n = 1298), missing second cancer
laterality (n = 25), and <6 months of follow-up after initial diagnosis (n = 663). This left a final
sample of 17,286.
All women were followed for 5 years from initial diagnosis until the first of the following:
second breast cancer, death, or the last day of available information from the cancer registry.
We identified 658 second DCIS and invasive breast cancers. Laterality and histology (ductal,
lobular or mixed, not otherwise specified or other) of the first and second invasive cancers
were compared to distinguish between recurrences and new primaries. Recurrences were
unilateral diagnoses in the ipsilateral breast and had to share the same histology as the primary
tumor (n = 314). We defined 344 second events as second primaries, including 15 bilateral
second events, 290 contralateral events, and 39 ipsilateral events whose histology differed from
that of the initial tumor.
Self-administered questionnaires were used to collect race/ethnicity, self-reported lump before
mammogram, menopausal status (last reported ≤6 months before first and second diagnosis),
and first-degree breast cancer family history reported before initial diagnosis. Breast density
was recorded by the interpreting radiologist using the Breast Imaging Reporting and Data
Systems [12] four density categories and was included only if recorded less than or equal to 2
years before the mammogram used for initial detection mode.
We used established methods combining mammogram indication and results to classify
detection mode at each diagnosis [13–15]. Mammograms were classified as screening (routine
screening without evidence of a self-reported lump ≤30 days before the mammogram leading
to the 1st diagnosis and with a radiologists’ indication for exam noted as screening) [13] or
diagnostic (additional evaluation of a recent mammogram, short-interval follow-up, evaluation
of a breast problem including self-reported presence of a breast lump by patient or provider
≤30 days before diagnosis) [16]. We used the earliest screening exam ≤365 days before
diagnosis to define detection mode. If the registry had no screening mammograms, we used
the earliest diagnostic mammogram ≤365 days before the diagnosis (Fig. 1) [17]. If no
mammogram was found ≤365 days before diagnosis, we used the first diagnostic mammogram
≤30 days after diagnosis, because diagnosis dates in tumor registries often represent the first
evidence of cancer.
Detection mode was defined as: screen-positive, screen-negative (interval cancer following a
negative screening exam), diagnostic-positive, or diagnostic-negative, using standard
definitions [13–15,18]. Mammograms with final BI-RADS® assessments of 4 or 5 were
considered “positive,” as were BI-RADS® assessments of 3 or 0 with a biopsy
recommendation, surgical consult or fine needle aspiration. All others were considered
“negative.” The same strategy was used for the second diagnosis, with the added restriction
that the mammogram had to follow the first cancer workup.
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Frequency distributions were computed for characteristics of women and first cancers. These
were examined separately for three groups, those without a second cancer, those with a
recurrence, and those with a second primary cancer. Cross-tabulations of initial detection mode
and self-reported lump by detection mode of the second cancer were done separately by second
breast event.
A surveillance mammogram was defined as any mammogram ≥6 months after the work-up of
the first cancer and before the second cancer. Kaplan–Meier curves were used to summarize
the relations between first cancer characteristics and surveillance mammography receipt.
We computed recurrence and new primary rates/1,000 woman years with 95% confidence
intervals (CI) calculated on the Poisson distribution. We plotted the Nelson–Aalen estimate of
the cumulative hazard function separately for each second events for certain characteristics.
We also plotted an estimate of the hazard function for second events to detect any incidence
peak.
We fit multivariable models using Cox regression to examine factors associated with second
events; different models were created for each risk factor (breast density, initial detection mode,
family history) and then one with all risk factors included. All models adjusted for stage,
adjuvant therapy, age at diagnosis, and registry. We used SAS 9.0 for most analyses and
generated hazard plots and multivariable models in Stata v.9.0.
Results
Stage I included 48.2% of the cohort, followed by stage II (33.1%), and DCIS (18.8%) (Table
1). Nearly 4% of the 17,286 women were diagnosed with a recurrence (N = 314) or second
primary (N = 344). Among second cancers, 4% were stage III/IV, 21% were stage II, 33% were
stage I, 22% were DCIS, and staging was unavailable for 19%.
At initial diagnosis, 35.8% of women were screen-detected, 15.6% screen interval-detected,
19.6% diagnostic detected, and 5.5% diagnostic interval-detected; 23.5% had an unknown
initial diagnosis mode.
Time to first surveillance mammogram was rapid in the year following initial diagnosis;
however, uptake did not markedly increase in the 18-months following diagnosis (Fig. 2a–c).
Women diagnosed with stage IIB cancer had a lower and slower uptake (Fig. 2a). Women who
were initially screen-detected were more likely to undergo surveillance than non screen-
detected (67% by 6-months and 83% by 12-months vs. 54–58% by 6-months and 71–76% by
12-months, respectively). Women with unknown detection mode had the slowest uptake (32%
by 6-months, 46% by 12-months) (Fig. 2b). Women receiving breast conserving surgery (BCS)
with radiation had the most rapid and greatest uptake (64% by 6-months, 78% by 12-months)
(Fig. 2c).
Overall second events rates/1,000 woman years were 5.37 for recurrence and 5.88 for second
primaries. Among women without a second event, 53% were followed for 5 years (mean = 47
months). As a sensitivity analysis, we included women from the initial cohort with missing
stage or surgery, multiple diagnoses in the initial 6-month period, bilateral cancer and missing
laterality of the second event and observed slightly higher recurrence rates (6.56/1,000 woman
years), but not of second primaries (6.03/1,000 woman years) (data not shown).
Initial stage was associated with recurrence and second primaries with the highest rates in
women with DCIS (8.5 and 7.4, respectively) and stage IIB (7.1 and 7.8) vs. stages I (3.9 and
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5.9) and IIA (5.3 and 3.8). Recurrence rates were higher for women with ER-negative tumors
than those with ER+ tumors; however, second primary rates were higher only for women with
ER−/PR− tumors. Second primary rates did not differ by primary therapy; however, recurrence
rates were higher in women with BCS without radiation (Table 2). Recurrence rates decreased
with increasing age at diagnosis, but rates of second primaries did not vary systematically
except among women aged ≥80 years, whose rates were markedly lower. Higher breast density
was associated with higher second primary rates (1.3 almost entirely fatty; 5.0 scattered
fibroglandular; 7.7 heterogeneously and extremely dense), but there was no trend in recurrence
rates.
Interval cancers accounted for 37.6% of recurrences and 36.3% of second primaries (data not
shown). We could not define diagnosis mode for 28.1% (32.2% for recurrences and 24.4% for
second primaries). Just over one-third of second events were diagnosed following a screening
(19.7% recurrence, 24.7% second primaries) or diagnostic mammogram (10.5, 14.5%,
respectively), and the rest were interval-detected following a screening (21.0, 21.2%) or a
diagnostic exam (16.6, 15.1%). Few women reported a lump before the mammogram leading
to their second cancer diagnosis: 8.0% of recurrences and 4.9% second primaries.
Some subgroups experienced higher recurrence rates, with no difference in second primaries,
including pre-menopausal women, node positive women, women who were initially detected
following a diagnostic mammogram, and women who initially had a self-reported lump.
Women with a family history had higher rates of second primaries but not of recurrence.
Notably, lower rates of second events were observed in women aged ≥80 years and adjuvant
hormonal therapy users.
Mode of initial diagnosis was the only variable that was significantly associated with risk of a
second cancer diagnosis after adjustment for other prognostic factors; women whose first
cancer was diagnostic detected had significantly higher risk of a second cancer compared to
women whose 1st cancer was screen-detected (Table 3). We conducted sensitivity analyses
that included all prognostic factors and varied the combination of risk factors; hazard estimates
did not vary in direction or significance in these sensitivity analyses and detection mode was
the only significant risk factor (data not shown).
Discussion
This study provides important information on timing and detection of second breast cancer
events after an initial diagnosis of early breast cancer. We identified certain subgroups with
higher second breast cancer event rates. Surveillance may be particularly important for women
<50 years or with initial DCIS, stage IIB, or ER – cancers as these subgroups had the highest
5-year cumulative hazards of recurrence and second primaries. Women with a family history
of breast cancer had higher rates of second primaries but not recurrences. The only subgroups
with a distinctly lower risk for either second event were women aged ≥80 years and those who
received adjuvant hormonal therapy.
Randomized trials [19–22] provide critical information on prognostic factors. However, initial
detection mode and breast density are less well understood as risk factors for second breast
events. It is important to understand whether detection mode and characteristics of patients and
tumors can be used to tailor surveillance recommendations to improve long-term outcomes,
particularly if women could benefit from more or less surveillance during certain times
following initial diagnosis. Our study was not designed to address the evidence gaps around
recommendations on when to stop surveillance mammography since we followed women for
only 5 years after initial diagnosis. It was designed to examine whether any characteristics of
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women or their initial tumors might be useful to guide recommendations around initial 5-year
surveillance after early stage breast cancer diagnosis.
Several studies and expert reviews have demonstrated surveillance mammography is effective
for improving long-term outcomes (e.g., breast cancer mortality) for women with early stage
breast cancer [3–5], including at least one study demonstrating decreased breast cancer
mortality [6]. Scrutiny of over-diagnosis from screening mammography has increased [23].
The concern is that mammography identifies breast lesions with limited potential for
malignancy and will trigger workup and treatment that may have no long-term impact on
mortality [23]. Inappropriate screening harms women and healthcare systems by increasing
anxiety and adding to unnecessary healthcare expenditures [24]. We know of no research that
has attempted to quantify over-diagnosis from surveillance mammograms. This is important
for breast cancer survivors, who may undergo additional treatment for a second cancer that
may not influence long-term outcomes.
We hypothesized that the mode of initial detection might affect second event rates and when
and how often women receive surveillance mammography. Women who were initially screen-
detected were more likely than others to return for their first surveillance mammogram [4].
Some mammography facilities routinely perform diagnostic examinations for anyone—even
asymptomatic patients—with a personal history of breast cancer, so it may be most appropriate
to compare detection mode of second events by combining screen- and diagnostic-detected vs.
interval-detected cancers. There are evidence gaps around how second breast cancer events
are detected. A systematic review [7] found extensive variation across 10 studies (N = 102–
7,000 patients) that reported on detection mode for recurrent breast cancers. In three studies,
73–88% of recurrences were detected from physical exam; this ranged from 12 to 54% in the
remaining seven studies [7]. The range was also large for the proportion of recurrences detected
by mammography (8–50%) [7]. Not surprisingly, Grunfeld’s review [7] found that recurrent
cancers detected by mammography were smaller and less invasive than were those detected
through physical exam. Isolating the effect of surveillance mammography on long-term
outcomes—such as mortality—remains challenging because of lead and length biases that
impact the timing of when second events are detected. However, recent studies have attempted
to isolate the influence of these biases, and findings keep suggesting that detection mode
remains an independent prognostic factor [25–27]. Consistent with recent literature [25–27],
women who were initially diagnosed following a diagnostic mammogram had significantly
higher risks of second events even after adjusting for prognostic factors; this further suggests
that mode of initial detection is an important prognostic factor for second cancer events.
Our finding that approximately 37% of second cancers were interval cancers serves as an
important reminder—women, radiologists, oncologists, and primary care providers need to
continue to be aware of newly arising symptoms and breast changes in both breasts (and chest
wall) even after a recent negative screening or diagnostic mammogram. Houssami et al. [27]
reported that 14% of second cancers were found by clinical breast exam alone. The absence
of a breast lump at presentation should not reassure clinicians since lumps were present in only
8% of recurrences and 5% of second primaries at the mammogram leading to the second
diagnosis; approximately 5% of women with no history of breast cancer report a breast lump
at the time of a screening mammogram [9].
The 5-year relative survival rates for DCIS have remained unchanged at around 100% [28].
Many studies examining surveillance mammography have not included women with DCIS
[6,26,29], who comprise ~20% of all breast cancer cases [30]. Importantly, in this study, women
with initial DCIS have substantially higher second cancer rates regardless of initial treatment.
This could reflect residual breast disease from initial diagnosis [31]. Clinically, this identifies
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an important sub-group of women who may benefit from increased surveillance mammography
since second breast cancer event rates in this population mirrored women with stage IIB tumors.
Although our findings confirmed that the vast majority of women receive a first surveillance
mammogram within 1-year of initial diagnosis, there are still opportunities to increase outreach
to populations who do not return for a mammogram within 18-months of initial diagnosis.
Examining surveillance mammography receipt is important for understanding timing and
detection mode of second breast events. In this study, we could not determine what type of
provider recommended surveillance or how women were reminded to receive mammography,
both of which affect uptake and adherence [32,33]. Continuity and coordination across health
care providers may help ensure high adherence to mammography surveillance [3,33,34].
Identifying and correctly distinguishing between recurrences and second primaries is
challenging and can be influenced by physician judgment, pathologists and available data from
initial diagnosis. Our definition of recurrence was stricter than others [35–38] because we
required the same laterality and histology. Previous studies have reported recurrence rates of
3%/year after DCIS, which is substantially higher than the 1%/year we observed. However,
our observed second primary rates (0.6%/year invasive and 0.8%/year DCIS) are consistent
with other cohorts [39,40]. Using pathology databases to identify second events has additional
limitations since some regional and distant recurrences may not have pathologic confirmation,
which leads to under-ascertainment of distant recurrences. This should not affect our second
breast cancer rates because they were ascertained through cancer registries. Distinguishing
between recurrences and second primaries may be less critical when considering surveillance
recommendations.
We limited our follow-up to 5 years because BCSC is not a closed cohort. We could not examine
second events by comorbidities. Also, even with our large sample, we lacked enough numbers
of women with stage IIIA (N = 581; 19 went on to have a recurrence (89% of these having a
regional recurrence) and 10 a second primary), so they were excluded. These women had a
significantly shorter time to second breast cancer, and most of them received chemotherapy.
Strengths of our study include: studying outcomes from community-based mammography
facilities in geographically diverse populations; including younger and older women; and
including second events that did not rely exclusively on tumor registries. We know of only one
other study that has included initial DCIS cases [27] and none that has included DCIS as a
second event. Approximately 20% of diagnoses of incident breast cancer are DCIS, so DCIS
is important for understanding the risk of second events.
Evidence to aid initial treatment decisions by using molecular markers will likely continue to
improve breast cancer outcomes [21,22]. However, we should not lose sight of our need to
continue to consider tailored surveillance recommendations. This study does not provide
evidence to support changing surveillance intervals for different subgroups. However, it does
suggest that certain subgroups may benefit from increased surveillance: women who are young
or have ER-negative tumors or DCIS or stage IIB disease. Surveillance may be less important
for older women (≥80 years) and for women using adjuvant hormonal therapy since rates of
second cancers were low in these women. These data can also be used to help counsel women
on detection mode for second cancers to seek care diligently for any symptoms that arise
following a negative mammogram.
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Mammograms used to define detection mode for first and second cancer events. Most patient
risk factors were based on responses to questionnaires completed within 6 months of the
mammogram used for initial mode of detection. Breast density was recorded by the interpreting
radiologist and was only included in the analysis if it was recorded within ≤2 years of the
mammogram used for initial mode of detection. Example Assume a woman has her first breast
cancer diagnosed on 1 January 2007. To determine the mode of detection we search for a
mammogram from 1 January 2006–1 January 2007. If none is found then we also look ahead
until 1 February 2007. Assume work-up of her first cancer finishes on 15 February 2007. We
then begin looking for a second breast cancer diagnosis 6 months later (after 16 August 2007)
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Time to first surveillance mammogram by characteristics of initial cancer. a By stage at first
diagnosis. b By mode of detection for initial diagnosis. c By treatment for initial diagnosis
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Table 3
Multivariable global hazard of having a second breast cancer event diagnosed adjusted for all variables in the
table
Model 4a (N = 8,662)
HR 95% CI P value
Breast density (before 1st diagnosis and within 2 years of mammogram used for mode of detection)
  Almost entirely fatty Ref 0.6859
  Scattered fibroglandular 1.07 (0.60, 1.90)
  Heterogeneously dense 1.20 (0.67, 2.13)
  Extremely dense 1.30 (0.68, 2.48)
Mode of 1st cancer diagnosis
  Screen-detected Ref 0.0008
  Screen interval-detected 1.38 (1.02, 1.86)
  Diagnostic detected 1.78 (1.35, 2.35)
  Diagnostic interval-detected 1.32 (0.86, 2.04)
1st degree family history of breast cancer (before 1st diagnosis)
  No Ref 0.9442
  Yes 1.01 (0.77, 1.32)
Age at 1st diagnosis
  18–39 1.06 (0.61–1.83) 0.6809
  40–49 0.99 (0.72–1.35)
  50–59 Ref
  60–69 1.08 (0.79–1.49)
  70–79 1.17 (0.84–1.65)
  80+ 0.76 (0.44–1.30)
Stage at 1st diagnosis
  0 1.66 (1.25–2.21) 0.003
  I Ref
  IIA 0.91 (0.66–1.26)
  IIB 1.12 (0.75–1.66)
Adjuvant therapy
  Neither Ref 0.0067
  Chemotherapy 1.22 (0.86–1.75)
  Hormonal 0.68 (0.51–0.93)
  Both 0.75 (0.47–1.18)
P values are based on likelihood ratio tests and are also adjusted for mammography registry
a
P ≤ 0.05
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